Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$105,000.00
The role of soluble CD163, a marker of adipose tissue macrophage activation, in the etiology of type 2 diabetes.
FY 2017-18
Summary
Overweight and obesity is the most well-established and impactful risk factor for the development of type 2diabetes mellitus (T2DM). Although a number of potential mechanisms have been suggested to explain the obesity-diabetes link, a great deal of research over the past 2 decades has focused on the role of persistent sub-clinical inflammation. Recently, the presence of macrophages in fat tissue was documented, demonstrating the potential importance of fat tissue as a key site of inflammation and source of inflammatory cell signaling proteins. Since direct assessment of fat tissue macrophages is not feasible in large population studies, research points to serum soluble CD163 (sCD163) a marker of macrophage activation. To date, limited data are available regarding the association of sCD163 with the progression of insulin resistance and pancreatic beta cell dysfunction key characteristics underlying T2DM. As well, less is known on factors that drive and initiate the progression of fat tissue inflammation. My Ph.D. research will address the current limitations through a long-term population study. I will use the PROspective Metabolism and Islet cell Evaluation (PROMISE) database that includes 712 individuals at high risk for developing T2DM. PROMISE includes demographic data, as well as glucose and insulin measures through Oral Glucose Tolerance Test from baseline, 3- and 6-year visits. Collected data will allow assessment of insulin sensitivity and beta-cell function over time. In addition, sCD163 and other important proteins will be measured through serum collections. The database will be used to understand how well sCD163 can predict T2DM development and its related pathology. As well, provide insight on traits that affect the development of inflammation. This will help us better grasp the obesity-diabetes relationship, as well as improve risk classification and potentially lead to new therapies in prevention or treatment of T2DM
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
383397
Name
Semnani-Azad Zhila
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Doctoral Research Awards - B
Projecttitle
The role of soluble CD163, a marker of adipose tissue macrophage activation, in the etiology of type 2 diabetes.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Adipose Tissue; Beta-Cell Function; Biomarkers; Diabetes, Type 2; Epidemiology; Inflammation; Insulin Sensitivity; Longitudinal Cohort; Macrophages
Abstract
Overweight and obesity is the most well-established and impactful risk factor for the development of type 2diabetes mellitus (T2DM). Although a number of potential mechanisms have been suggested to explain the obesity-diabetes link, a great deal of research over the past 2 decades has focused on the role of persistent sub-clinical inflammation. Recently, the presence of macrophages in fat tissue was documented, demonstrating the potential importance of fat tissue as a key site of inflammation and source of inflammatory cell signaling proteins. Since direct assessment of fat tissue macrophages is not feasible in large population studies, research points to serum soluble CD163 (sCD163) a marker of macrophage activation. To date, limited data are available regarding the association of sCD163 with the progression of insulin resistance and pancreatic beta cell dysfunction key characteristics underlying T2DM. As well, less is known on factors that drive and initiate the progression of fat tissue inflammation. My Ph.D. research will address the current limitations through a long-term population study. I will use the PROspective Metabolism and Islet cell Evaluation (PROMISE) database that includes 712 individuals at high risk for developing T2DM. PROMISE includes demographic data, as well as glucose and insulin measures through Oral Glucose Tolerance Test from baseline, 3- and 6-year visits. Collected data will allow assessment of insulin sensitivity and beta-cell function over time. In addition, sCD163 and other important proteins will be measured through serum collections. The database will be used to understand how well sCD163 can predict T2DM development and its related pathology. As well, provide insight on traits that affect the development of inflammation. This will help us better grasp the obesity-diabetes relationship, as well as improve risk classification and potentially lead to new therapies in prevention or treatment of T2DM
Competitiondate
201710
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Semnani-Azad, Zhila
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~